11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases
Glucocorticoids (GCs), which are secreted by the adrenal cortex, are important regulators in the metabolism of carbohydrates, lipids, and proteins. For the proper functioning of the body, strict control of their release is necessary, as increased GCs levels may contribute to the development of obesi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/16/8984 |
| _version_ | 1797409817132793856 |
|---|---|
| author | Daria Kupczyk Rafał Bilski Mariusz Kozakiewicz Renata Studzińska Kornelia Kędziora-Kornatowska Tomasz Kosmalski Agnieszka Pedrycz-Wieczorska Mariola Głowacka |
| author_facet | Daria Kupczyk Rafał Bilski Mariusz Kozakiewicz Renata Studzińska Kornelia Kędziora-Kornatowska Tomasz Kosmalski Agnieszka Pedrycz-Wieczorska Mariola Głowacka |
| author_sort | Daria Kupczyk |
| collection | DOAJ |
| description | Glucocorticoids (GCs), which are secreted by the adrenal cortex, are important regulators in the metabolism of carbohydrates, lipids, and proteins. For the proper functioning of the body, strict control of their release is necessary, as increased GCs levels may contribute to the development of obesity, type 2 diabetes mellitus, hypertension, cardiovascular diseases, and other pathological conditions contributing to the development of metabolic syndrome. 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) locally controls the availability of the active glucocorticoid, namely cortisol and corticosterone, for the glucocorticoid receptor. Therefore, the participation of 11β-HSD1 in the development of metabolic diseases makes both this enzyme and its inhibitors attractive targets in the pharmacotherapy of the above-mentioned diseases. |
| first_indexed | 2024-03-09T04:20:59Z |
| format | Article |
| id | doaj.art-7c79918d3d824c748bc30b5f4201acea |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T04:20:59Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7c79918d3d824c748bc30b5f4201acea2023-12-03T13:47:44ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-08-012316898410.3390/ijms2316898411β-HSD as a New Target in Pharmacotherapy of Metabolic DiseasesDaria Kupczyk0Rafał Bilski1Mariusz Kozakiewicz2Renata Studzińska3Kornelia Kędziora-Kornatowska4Tomasz Kosmalski5Agnieszka Pedrycz-Wieczorska6Mariola Głowacka7Department of Medical Biology and Biochemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Karłowicza 24, 85-092 Bydgoszcz, PolandDepartment of Medical Biology and Biochemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Karłowicza 24, 85-092 Bydgoszcz, PolandDepartment of Geriatrics, Nicolaus Copernicus University in Toruń, L. Rydygier Collegium Medicum in Bydgoszcz, Dębowa 3, 85-626 Bydgoszcz, PolandDepartment of Organic Chemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Jurasza 2, 85-089 Bydgoszcz, PolandDepartment of Geriatrics, Nicolaus Copernicus University in Toruń, L. Rydygier Collegium Medicum in Bydgoszcz, Dębowa 3, 85-626 Bydgoszcz, PolandDepartment of Organic Chemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Jurasza 2, 85-089 Bydgoszcz, PolandDepartment of Histology and Embriology, Medical University in Lublin, Radziwiłłowska 11, 20-080 Lublin, PolandFaculty of Health Sciences, Mazovian State University in Płock, Plac Dąbrowskiego 2, 09-402 Płock, PolandGlucocorticoids (GCs), which are secreted by the adrenal cortex, are important regulators in the metabolism of carbohydrates, lipids, and proteins. For the proper functioning of the body, strict control of their release is necessary, as increased GCs levels may contribute to the development of obesity, type 2 diabetes mellitus, hypertension, cardiovascular diseases, and other pathological conditions contributing to the development of metabolic syndrome. 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) locally controls the availability of the active glucocorticoid, namely cortisol and corticosterone, for the glucocorticoid receptor. Therefore, the participation of 11β-HSD1 in the development of metabolic diseases makes both this enzyme and its inhibitors attractive targets in the pharmacotherapy of the above-mentioned diseases.https://www.mdpi.com/1422-0067/23/16/898411β-HSD enzyme11β-HSD1 inhibitorsmetabolic syndromeglucocorticoidsdiabetes mellitusobesity |
| spellingShingle | Daria Kupczyk Rafał Bilski Mariusz Kozakiewicz Renata Studzińska Kornelia Kędziora-Kornatowska Tomasz Kosmalski Agnieszka Pedrycz-Wieczorska Mariola Głowacka 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases International Journal of Molecular Sciences 11β-HSD enzyme 11β-HSD1 inhibitors metabolic syndrome glucocorticoids diabetes mellitus obesity |
| title | 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases |
| title_full | 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases |
| title_fullStr | 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases |
| title_full_unstemmed | 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases |
| title_short | 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases |
| title_sort | 11β hsd as a new target in pharmacotherapy of metabolic diseases |
| topic | 11β-HSD enzyme 11β-HSD1 inhibitors metabolic syndrome glucocorticoids diabetes mellitus obesity |
| url | https://www.mdpi.com/1422-0067/23/16/8984 |
| work_keys_str_mv | AT dariakupczyk 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT rafałbilski 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT mariuszkozakiewicz 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT renatastudzinska 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT korneliakedziorakornatowska 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT tomaszkosmalski 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT agnieszkapedryczwieczorska 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases AT mariolagłowacka 11bhsdasanewtargetinpharmacotherapyofmetabolicdiseases |